Literature DB >> 20035216

Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure.

Lena M Napolitano1, Pauline K Park, Krishnan Raghavendran, Robert H Bartlett.   

Abstract

Severe respiratory failure (including acute lung injury and acute respiratory distress syndrome) caused by 2009 H1N1 influenza infection has been reported worldwide. Refractory hypoxemia is a common finding in these patients and can be challenging to manage. This review focuses on nonventilatory strategies in the advanced treatment of severe respiratory failure and refractory hypoxemia such as that seen in patients with severe acute respiratory distress syndrome attributable to 2009 H1N1 influenza. Specific modalities covered include conservative fluid management, prone positioning, inhaled nitric oxide, inhaled vasodilatory prostaglandins, and extracorporeal membrane oxygenation and life support. Pharmacologic strategies (including steroids) investigated for the treatment of severe respiratory failure are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20035216     DOI: 10.1097/CCM.0b013e3181cc5373

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

Review 1.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

Review 2.  Extracorporeal life support for pandemic influenza: the role of extracorporeal membrane oxygenation in pandemic management.

Authors:  Ed DeLaney; Michael J Smith; Brian T Harvey; Keith J Pelletier; Michael P Aquino; Justin M Stone; Gerald C Jean-Baptiste; Julie H Johnson
Journal:  J Extra Corpor Technol       Date:  2010-12

3.  Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trial.

Authors:  Jostein Skjalg Hagemo; Arne Kristian Skulberg; Marius Rehn; Morten Valberg; Maiju Pesonen; Hans Julius Heimdal; Fridtjof Heyerdahl
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

4.  Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza.

Authors:  Ilyse Darwish; Chris Miller; Kevin C Kain; W Conrad Liles
Journal:  Int J Med Sci       Date:  2012-01-13       Impact factor: 3.738

5.  Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases.

Authors:  Matthias Lubnow; Alois Philipp; Maik Foltan; Tone Bull Enger; Dirk Lunz; Thomas Bein; Assad Haneya; Christof Schmid; Günter Riegger; Thomas Müller; Karla Lehle
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 6.  Targeting the Linear Ubiquitin Assembly Complex to Modulate the Host Response and Improve Influenza A Virus Induced Lung Injury.

Authors:  Patricia L Brazee; Jacob I Sznajder
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-05-13       Impact factor: 4.872

Review 7.  Human Influenza Virus Infections.

Authors:  Christin Peteranderl; Susanne Herold; Carole Schmoldt
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

Review 8.  Therapeutics against influenza.

Authors:  Elena A Govorkova; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  Linear ubiquitin assembly complex regulates lung epithelial-driven responses during influenza infection.

Authors:  Patricia L Brazee; Luisa Morales-Nebreda; Natalia D Magnani; Joe Gn Garcia; Alexander V Misharin; Karen M Ridge; G R Scott Budinger; Kazuhiro Iwai; Laura A Dada; Jacob I Sznajder
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 10.  Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO.

Authors:  Alberto Zangrillo; Giuseppe Biondi-Zoccai; Giovanni Landoni; Giacomo Frati; Nicolò Patroniti; Antonio Pesenti; Federico Pappalardo
Journal:  Crit Care       Date:  2013-02-13       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.